Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal
tumour after failure of imatinib: a randomised controlled trial.
Efficacy and safety of regorafenib for advanced gastrointestinal stromal
tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo - controlled, phase 3 trial.
Not exact matches
And in 2010, a 46 - year - old woman developed multiple
tumours in her kidney
after having her own bone marrow stem cells injected at a private clinic in an attempt to treat her kidney
failure.